Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.61 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25741114 | 0.90 | CRBN (0.60) | IKZF2CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL25283238 | 0.90 | CRBN (0.60) | IKZF2CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL25242642 | 0.90 | CRBN (0.60) | IKZF2CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL25741115 | 0.88 | CRBN (0.57) | IKZF2CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL29480083 | 0.88 | CRBN (0.65) | IKZF2CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL17432016 | 0.88 | CRBN (0.65) | IKZF2CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL25740848 | 0.88 | CRBN (0.67) | IKZF2CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL23589813 | 0.86 | CRBN (0.65) | IKZF2CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL15128599 | 0.86 | CRBN (0.68) | IKZF2CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL23657092 | 0.85 | CRBN (0.61) | IKZF2CRBNGSPT1DDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220388985-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388985-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | IKZF2 1760/4885CRBN 422/4885GSPT1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.